• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pfizer Under The Gun

Pfizer Under The Gun

January 23, 2007
CenterWatch Staff

Well, Pfizer made its big news official yesterday. The company plans to cut 10,000 jobs—about 10% of the company—by the end of 2008 and close some facilities, including three research sites in the United States. The job cuts and site closings are expected to save $2 billion a year.

To me, what is important is the company’s research plans. The three research sites set to close are all in Michigan, but don’t include a large manufacturing facility in the state and Animal Health. The company is also looking at shutting down research sites in Nagoya, Japan and Amboise, France.

“These and other actions will allow us to reduce costs in support services and ‘bricks and mortar’ and to redeploy hundreds of millions of dollars into the discovery and development work of our scientists,” Dr. John LaMattina, head of Pfizer Global Research and Development, said in a statement.

Pfizer’s long list of problems, from intense generic competition to its recent failure to get cholesterol drug torcetrapib through clinical trials, have been well documented here and in many other places. Once that big pipeline failure was announced last month, it was clear that Jeffrey Kindler, Pfizer’s chairman and chief executive officer, would take dramatic action.

But just cost cutting won’t do it. If Pfizer is to right itself, it must fill huge revenue gaps with new, big-selling drugs. To help find those drugs, the company said it will simplify its R&D organization. The company hopes to improve productivity by consolidating research teams focused on a particular therapeutic area to one of four big sites. These research teams are currently in multiple locations around the world. It’s a tall order.

Pfizer can’t catch a break. The AIDS Healthcare Foundation told Reuters it plans to take legal action against Pfizer in an attempt to stop the company from allegedly marketing its erectile dysfunction drug as a sexual enhancement. Pfizer denies the accusation. The AIDS organization claims the marketing of Viagra has led to risky behavior by men and an increase in HIV.

Pfizer’s announcement yesterday essentially admitted that its R&D efforts have a long way to go. And the AIDS group’s lawsuit took aim at one of the most productive areas of big pharma companies: marketing. At each end of the drug pipeline, Pfizer is under fire. The company must make its own breaks by simplifying R&D and producing new drugs.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing